Metabolism Drugs Market Size Is Estimated to Witness a CAGR of 6.3% By 2026, Finds Coherent Market Insights
SEATTLE, April 08, 2021, (PHARMIWEB) — Metabolism involves breaking down of carbohydrates, proteins, and fats present in the consumed food, to generate energy. It also includes the excretion of nitrogen through urine, and breaking down or converting other substances and chemicals. Metabolism disorder is resultant of improper functioning of the body’s metabolism but it can also have a genetic origin as it can be caused by genetic birth defects as well. However, metabolic disorder has a low incidence and prevalence rate. Metabolism disorder usually caused by inadequate production of enzymes and proteins by the body or produced proteins do not function the way they should.
The metabolic disorder mostly occurs due to the accumulation of protein, glycogen, lipids, urea, toxic substance, and calcium stones in the body and each of them has certain metabolic pathways and metabolic agents. So when these agents do not perform their task properly it leads to a buildup of the molecule in the blood and other places. Some of the metabolic diseases are Gaucher disease, hereditary orotic, aciduria, tyrosinemia, and Fabry disease.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1955
Growing prevalence of the metabolic disease is projected to favor the market growth of the metabolism drugs market over the forecast period
Metabolic diseases disrupt the process of converting food to energy on a cellular level and are difficult to treat. For instance, obesity is the most common type of metabolic disorder and is closely related to metabolic syndrome (a cluster of clinical conditions such as high blood sugar and triglycerides). According to the World Health Organization (WHO), over 650 million people aged 18 years and above were obese in 2016.
Another condition called lysosomal storage disease is a rare disorder, however, a significant number of people are affected by this disease. According to a study published in Molecular Genetics and Metabolism Reports in December 2017, lysosomal storage disease has an incidence rate of 1 in 4000 to 1 in 13,000 live births. Lysosomal storage disease consists of 60 genetic abnormalities with problematic enzyme function.
Moreover, other rare diseases such as Hunter syndrome (Mucopolysaccaridosis type II (MPS II)), though rare, are life-threatening diseases with no curative treatment available, thus patients are made to rely on available therapies. According to the National Institute of Health 2018 report, the Frequency of MPS II is 1 in 100,000 to 1 in 160,000 in males. Increasing the incidence of hunter syndrome is expected to boost the metabolism disease drug market. For instance, in 2014, around 970 patients were enrolled in the Hunter Outcome Survey (HOC), which increased to 1195 patients in 2017.
The global metabolism drugs market size was valued at US$ 5,765.3 million in 2017 and is expected to witness a robust CAGR of 6.3% over the forecast period (2018 – 2026).
Figure 1. Global Metabolism Drugs Market Share US$ Mn, by Region, 2018
Source: Coherent Market Insights Analysis (2018)
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1955
Introduction of a new therapy is expected to boost the growth of the metabolism drugs market over the forecast period
Key players are trying to an introduced new therapy for treating rare metabolism disorders in order to meet the demand. Though the prevalence of rare diseases is low, patients rely on therapies that are made available irrespective of their price. These drugs are difficult to produce, and in turn expensive, still, developers are creating therapies for chronic and difficult-to-cure rare diseases, selling them at higher prices.
Approvals to innovative therapies such as enzyme replacement therapy are expected to influence manufacturers to develop novel therapies in the market. This, in turn, is expected to support the metabolism drugs market growth over the forecast period. The U.S. Food and Drug Administration (FDA) approved multiple drugs for Gaucher disease. For instance, in 2010, FDA approved Vpriv (velaglucerase alfa), an enzyme replacement therapy (ERT), for type 1 Gaucher disease. In 2012, Elelyso (taliglucerase alfa) and in 2014, Cerdelga (eliglustat) was approved by the FDA for type 1 Gaucher disease.
Moreover, the rising number of research and development of novel therapies for the treatment of rare metabolism diseases such as Pompe, and others are projected to boost market growth. For instance, in October 2017, Amicus Therapeutics received orphan drug designation to ATB200/AT2221 from the U.S. FDA for the treatment of Pompe disease. Moreover, novel gene and RNAi therapies are also under research for the treatment of these diseases.
On the other side, the high cost associated with the treatment and long duration of the treatments is expected to hamper the growth of the metabolism drugs market. For instance, according to a research paper published by Harvard School, in 2016, Lumizyme accounted for US$ 100,000 per year for children and US$ 300,000 per year for adult treatments for Pompe disease.
Figure 2. Global Metabolism Drugs Market Share (%), by Application, 2018
Source: Coherent Market Insights Analysis (2018)
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/metabolism-drugs-market-to-surpass-us-99-billion-threshold-by-2026-globally-1015
Some of the major players operating in the global metabolism drugs market include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- PEST Analysis
- PORTER’s Analysis
- Regulatory Scenario
- Market Dynamics
- Global Metabolism Drugs Market, By Therapy Type, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Substrate Reduction Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Small Molecule Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Metabolism Drugs Market, By Application, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Glycogen Metabolism Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Lipid Metabolism Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Amino Acid Metabolism Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Metabolism Drugs Market, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, 2017 – 2026
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Mn)
- Introduction
- Global Metabolism Drugs Market, By Regions, 2016 – 2026 (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2018 and 2026 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2026
- North America
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of APAC
- Latin America
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- Central Africa
- South Africa
- North Africa
- Middle East
- Market Size and Forecast, By Therapy Type, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2026 (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2026 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Introduction
- Competitive Landscape
- Company Profiles
- Section
- References
- Research Methodology
- About Us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
